Aspesberro François, Guthrie Katherine A, Woolfrey Ann E, Brogan Thomas V, Roberts Joan S
Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
J Intensive Care Med. 2014 Jan-Feb;29(1):31-7. doi: 10.1177/0885066612457343. Epub 2012 Aug 17.
To assess the risk factors for intensive care unit admission among children receiving hematopoietic stem cell transplantation (HSCT) and to test the hypothesis that multiple organ failure (MOF) increases the odds of death among HSCT patients who receive mechanical ventilation (MV).
The chart of all consecutive HSCTs at Seattle Children's Hospital and pediatric HSCT patients admitted to the pediatric critical care unit of a tertiary care pediatric hospital from January 2000 to September 2006 were reviewed retrospectively.
Charts of 266 HSCT patients were reviewed. Nonmalignant disease compared to hematologic malignancy, acute graft versus host disease grades III and IV, and second transplant increased the odds of pediatric intensive care unit admission. Among patients receiving MV for >24 hours, 9 (25%) survived for 6 months, while 8 patients (22%) were long-term survivors with a median follow-up time of 3.6 years, a significant improvement compared to a long-term survival of 7% (odds ratio 0.25, 95% confidence intervals: 0.09-0.72, P = .01) reported in a previously published cohort of pediatric HSCT patients at the same institution from 1983 to 1996. Cardiovascular failure, duration of MV for greater than 1 week, and prolonged receipt of continuous renal replacement therapy (CRRT) increased the risk of mortality.
Six-month survival of pediatric HSCT patients was 25% and the odds of death were increased by cardiovascular failure but not by MOF. Receipt of mechanical support (ventilation, CRRT) or cardiovascular support (inotropic agents) decreased the likelihood of long-term survival.
评估接受造血干细胞移植(HSCT)的儿童入住重症监护病房的危险因素,并检验多器官功能衰竭(MOF)会增加接受机械通气(MV)的HSCT患者死亡几率这一假设。
回顾性分析了2000年1月至2006年9月在西雅图儿童医院接受的所有连续性HSCT病例以及入住一家三级儿科医院儿科重症监护病房的儿科HSCT患者病历。
对266例HSCT患者的病历进行了回顾。与血液系统恶性肿瘤相比,非恶性疾病、急性移植物抗宿主病III级和IV级以及二次移植增加了儿科重症监护病房入住几率。在接受MV超过24小时的患者中,9例(25%)存活6个月,而8例患者(22%)为长期存活者,中位随访时间为3.6年,与1983年至1996年在同一机构发表的先前儿科HSCT患者队列中报告的7%长期存活率相比有显著改善(优势比0.25,95%置信区间:0.09 - 0.72,P = 0.01)。心血管衰竭、MV持续时间超过1周以及持续接受肾脏替代治疗(CRRT)时间延长增加了死亡风险。
儿科HSCT患者的6个月生存率为25%,心血管衰竭会增加死亡几率,但MOF不会。接受机械支持(通气、CRRT)或心血管支持(血管活性药物)会降低长期存活的可能性。